Skip to main content
. 2020 Apr 9;9(4):1067. doi: 10.3390/jcm9041067

Table 2.

Pharmacokinetic parameters for linezolid. Entries are the median [interquartile range], estimate (95% confidence interval), or count (%). The p-values refer to comparisons of the obese and non-obese groups. AUC = area under the concentration–time curve; CL = total body clearance; ISF = interstitial fluid of the subcutaneous adipose tissue; MRT = mean resistance time; Vss = volume of distribution at a steady state; Cmax = maximum concentration; t1/2 = half-life; Tmax = time point of Cmax. Bold type indicates significant values.

All Patients
(n = 30)
Pearson’s Correlation Coefficient with Weight Obese
(n = 15)
Non-Obese
(n = 15)
p-Value
Cmax (mg/L)
ISF 5.5 [3.8, 8.5] −0.70 (−0.85 to −0.45) 3.8 [3.2, 5.3] 8.3 [5.7, 10.2] <0.001
Plasma (total) 21.9 [17.2, 24.4] −0.63 (−0.81 to −0.36) 19.2 [16.1, 22.1] 24.4 [18.9, 26.9] 0.013
Plasma (unbound) 18.5 [14.4, 21.1] −0.66 (−0.82 to −0.39) 15.9 [13.3, 18.7] 21.1 [16.6, 23.3] 0.007
t1/2 (hours)
ISF 3.9 [2.8, 4.8] 0.11 (−0.26 to 0.45) 3.9 [2.7, 5.1] 3.8 [3.0, 4.2] 0.664
Plasma (total and unbound) 3.4 [2.6, 4.4] 0.52 (0.20 to 0.74) 3.8 [3.0, 4.8] 3.0 [2.5, 3.6] 0.088
Vss (L), plasma 37.7 [31.3, 44.6] 0.87 (0.75 to 0.94) 41.0 [38.4, 57.9] 30.8 [27.9, 35.5] <0.001
CL (L/h), plasma 7.2 [6.3, 9.3] 0.21 (−0.16 to 0.53) 8.2 [6.2, 10.8] 7.0 [6.4, 8.2] 0.170
MRT (h), plasma 5.0 [3.8, 6.3] 0.47 (0.13 to 0. 71) 5.7 [4.5, 6.9] 4.4 [3.8, 5.4] 0.079
Tmax, ISF 30–60/60–90/>90 min (number of patients) 17/3/10 7/3/5 10/0/5 0.252
AUC0-8, (mg*h/L)
ISF 29.4 [23.5, 37.8] −0.61 (−0.80 to −0.32) 23.7 [20.2, 28.1] 34.4 [29.4, 45.5] 0.004
Plasma (total) 63.4 [52.8, 71.1] −0.66 (−0.82 to −0.39) 57.9 [45.4, 65.6] 67.8 [61.5, 80.5] 0.011
Plasma (unbound) 54.5 [45.6, 61.5] −0.68 (−0.84 to −0.43) 47.7 [39.7, 56.7] 59.6 [51.7, 70.8] 0.005
AUC0–8 ISF/fAUC0–8 plasma 0.53 [0.46, 0.65] −0.28 (−0.58 to 0.09) 0.53 [0.45, 0.55] 0.62 [0.53, 0.68] 0.080